文献速递白血病MDS 与骨髓增殖性肿瘤

儿童期暴露于低剂量(<100 mSv)电离辐射者的白血病与髓系恶性肿瘤:九项历史队列研究的汇总分析

Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies.
PubMed 文献 · Lancet Haematol · 2018-07-17

该汇总分析纳入来自加拿大、法国、日本、瑞典、英国和美国的九项历史队列,共262573名首次照射时年龄<21岁、平均累积活动骨髓剂量<100 mSv者;100 mSv时急性髓系白血病与骨髓增生异常综合征合并的相对风险为3.09(95%CI 1.41-5.92),急性淋巴细胞白血病为5.66(95%CI 1.35-19.71),慢性髓系白血病未见明确剂量反应。

要点

  • 儿童期累积活动骨髓剂量<100 mSv时,急性髓系白血病与骨髓增生异常综合征合并及急性淋巴细胞白血病的风险显著增加。
  • 100 mSv时急性髓系白血病与骨髓增生异常综合征合并相对风险3.09(95%CI 1.41-5.92),急性淋巴细胞白血病5.66(95%CI 1.35-19.71)。
  • 部分终点在累积剂量<50 mSv时剂量反应仍显著,慢性髓系白血病未见明确剂量反应。

核心结论

  • 儿童或青少年期累积电离辐射剂量<100 mSv后,急性髓系白血病和急性淋巴细胞白血病风险显著增加,部分终点在累积剂量<50 mSv时也可见超额风险。
  • 这些发现支持低剂量辐射暴露与白血病风险增加相关,并提示现行辐射防护体系是审慎的而非过度防护。

研究设计与样本

  • 历史队列研究的汇总分析,汇总截至2014年6月30日报告的合格队列。
  • 纳入标准包括未因恶性疾病接受治疗、报告至少5例相关造血系统肿瘤、并估计了个体活动骨髓剂量。
  • 分析限于首次照射时年龄<21岁且平均累积活动骨髓剂量<100 mSv的个体,采用泊松回归拟合剂量反应模型。
  • 共识别来自加拿大、法国、日本、瑞典、英国和美国的九项合格队列,纳入262573名于1915年6月4日至2004年12月31日入组且暴露<100 mSv者。
  • 平均随访19.63年(SD 17.75),平均累积活动骨髓剂量19.6 mSv(SD 22.7)。

主要发现

  • 共识别154例髓系恶性肿瘤(包括79例急性髓系白血病、8例骨髓增生异常综合征、36例慢性髓系白血病及其他未特指髓系恶性肿瘤)和40例急性淋巴细胞白血病,总计识别221例白血病(包括其他未分类白血病但排除慢性淋巴细胞白血病)。
  • 100 mSv时拟合相对风险:急性髓系白血病与骨髓增生异常综合征合并为3.09(95%CI 1.41-5.92;ptrend=0.008)。
  • 100 mSv时拟合相对风险:急性髓系白血病为2.56(95%CI 1.09-5.06;ptrend=0.033)。
  • 100 mSv时拟合相对风险:急性淋巴细胞白血病为5.66(95%CI 1.35-19.71;ptrend=0.023)。
  • 慢性髓系白血病未见明确剂量反应,100 mSv时相对风险为0.36(95%CI 0.00-2.36;ptrend=0.394)。

关键数值与推荐

  • 急性髓系白血病与骨髓增生异常综合征合并及急性淋巴细胞白血病的剂量反应在剂量<50 mSv时仍显著。
  • 队列间异质性或偏离线性的迹象很少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Substantial evidence links exposure to moderate or high doses of ionising radiation, particularly in childhood, with increased risk of leukaemia. The association of leukaemia with exposure to low-dose (<100 mSv) radiation is less certain, although this is the dose range most relevant to the general population. We aimed to estimate the risk of leukaemia associated with low-dose radiation exposure in childhood (age <21 years). METHODS: In this analysis of historical cohort studies, we pooled eligible cohorts reported up to June 30, 2014. We evaluated leukaemia and myeloid malignancy outcomes in these cohorts with the relevant International Classification of Diseases and International Classification of Diseases for Oncology definitions. The cohorts included had not been treated for malignant disease, had reported at least five cases of the relevant haematopoietic neoplasms, and estimated individual active bone marrow (ABM) doses. We restricted analysis to individuals who were younger than 21 years at first irradiation who had mean cumulative ABM doses of less than 100 mSv. Dose-response models were fitted by use of Poisson regression. The data were received in fully anonymised form by the statistical analyst. FINDINGS: We identified nine eligible cohorts from Canada, France, Japan, Sweden, the UK, and the USA, including 262 573 people who had been exposed to less than 100 mSv enrolled between June 4, 1915, and Dec 31, 2004. Mean follow-up was 19·63 years (SD 17·75) and mean cumulative ABM dose was 19·6 mSv (SD 22·7). 154 myeloid malignancies were identified (which included 79 acute myeloid leukaemias, eight myelodysplastic syndromes, and 36 chronic myeloid leukaemias, in addition to other unspecified myeloid malignancies) and 40 acute lymphoblastic leukaemias, with 221 leukaemias (including otherwise unclassified leukaemias but excluding chronic lymphocytic leukaemia) identified overall. The fitted relative risks at 100 mSv were 3·09 (95% CI 1·41-5·92; ptrend=0·008) for acute myeloid leukaemia and myelodysplastic syndromes combined, 2·56 (1·09-5·06; ptrend=0·033) for acute myeloid leukaemia, and 5·66 (1·35-19·71; ptrend=0·023) for acute lymphoblastic leukaemia. There was no clear dose-response for chronic myeloid leukaemia, which had a relative risk at 100 mSv of 0·36 (0·00-2·36; ptrend=0·394). There were few indications of between-cohort heterogeneity or departure from linearity. For acute myeloid leukaemia and myelodysplastic syndromes combined and for acute lymphoblastic leukaemia, the dose-responses remained significant for doses of less than 50 mSv. Excess absolute risks at 100 mSv were in the range of 0·1-0·4 cases or deaths per 10 000 person-years. INTERPRETATION: The risks of acute myeloid leukaemia and acute lymphoblastic leukaemia were significantly increased after cumulative doses of ionising radiation of less than 100 mSv in childhood or adolescence, with an excess risk also apparent for cumulative radiation doses of less than 50 mSv for some endpoints. These findings support an increased risk of leukaemia associated with low-dose exposure to radiation and imply that the current system of radiological protection is prudent and not overly protective. FUNDING: National Cancer Institute Intramural Research Program, National Cancer Institute, and US National Institutes for Health.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Little MP, Wakeford R, Borrego D, et al. Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies. Lancet Haematol. 2018. PMID: 30026010. doi:10.1016/S2352-3026(18)30092-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。